Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.37 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228461 | 0.88 | ESR1 (0.41) | ESR1ESR2 | |
| SCHEMBL224396 | 0.86 | ESR1 (0.43) | ESR1ESR2MMP1MMP9MMP13 | |
| SCHEMBL228870 | 0.81 | ESR1 (0.51) | ESR1ESR2MMP1MMP9MMP13 | |
| SCHEMBL226089 | 0.79 | ESR1 (0.40) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL226140 | 0.78 | ESR1 (0.47) | ESR1ESR2MMP1MMP9MMP13 | |
| SCHEMBL4480980 | 0.78 | ESR1 (0.47) | ESR1ESR2MMP1MMP9MMP13 | |
| SCHEMBL227845 | 0.78 | ESR1 (0.45) | ESR1ESR2MMP1MMP9MMP13 | |
| SCHEMBL227618 | 0.77 | LTA4H (0.41) | ESR1ESR2MMP1MMP9MMP13 | |
| SCHEMBL228396 | 0.77 | ESR1 (0.47) | ESR1ESR2HRH3 | |
| SCHEMBL228873 | 0.77 | LTA4H (0.40) | ESR1ESR2MMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885MMP1 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.